Friday, September 11, 2026

Takeda announces planned retirement of R&D chief Andy Plump

Takeda is preparing a leadership change in research and development. Andy Plump, M.D., Ph.D., President Research & Development and a member of the Board of Directors, is scheduled to retire from the company in June 2027.

Plump will remain on Takeda’s Executive Team and continue to lead R&D until a successor is announced. He is also expected to stay on the Board of Directors through the Ordinary General Meeting of Shareholders in June 2027. Once a new R&D president has been named, Takeda plans a transition period between the two executives.

R&D transformation since 2015

Plump joined Takeda in 2015 and, according to the company, played a central role in its development into a more globally oriented biopharmaceutical group. His tenure included a sharper innovation focus, a more streamlined global footprint and prioritization across selected therapeutic areas.

CEO Julie Kim highlighted Plump’s contribution to rebuilding Takeda’s late-stage pipeline and strengthening the R&D organization. The company also pointed to partnerships as well as approved and investigational therapies developed during this period.

Under Plump’s leadership, Takeda received U.S. FDA approval for ORZEYFUL in narcolepsy type 1. The company also secured approval for MIMRYLO for erythrocytosis in adults with polycythemia vera.

Pipeline and growth strategy

The upcoming change comes as Takeda advances its two-horizon growth strategy. The first horizon focuses on new medicine launches, progress in the late-stage pipeline, resilience of core in-line brands and new capabilities and efficiencies. The second horizon is intended to build on that base by scaling launches, introducing further pipeline products and improving speed through advanced technology.

Takeda cited zasocitinib, a selective TYK2 inhibitor for oral psoriasis treatment, among its Phase 3 assets. During the transition, the company aims to maintain momentum around global regulatory submissions and approvals.